Phase I, Multicenter, Randomized, Open-Label Study Evaluating the Pharmacokinetics and Safety Profile of Repeated Once-Daily Doses of Intravenous Esomeprazole in Children 0 to 17 Years of Age

Clinical Therapeutics

Volumn 34, Issue 8, 2012, Pages 1828-1838

  Sandström, Marie ^a   Davidson, Geoffrey ^b   Tolia, Vasundhara ^c   Sullivan, Janice E ^d   Långström, Göran ^a   Lundborg, Per ^a   Brown, Kurt ^e  

^a ASTRAZENECA R AND D   (Sweden)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c PROVIDENCE HOSPITAL   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Adolescents; Gastroesophageal reflux; GERD; Infant; Pediatrics; Proton pump inhibitor

Indexed keywords

ANTIBIOTIC AGENT; ESOMEPRAZOLE;

ABDOMINAL ABSCESS; ACUTE RESPIRATORY FAILURE; ADOLESCENT; ADOLESCENT DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; AFRICAN AMERICAN; AGE DISTRIBUTION; AGITATION; ANTIBIOTIC THERAPY; ARTICLE; ASIAN; BLOOD PRESSURE; BLOOD SAMPLING; BODY WEIGHT; BRONCHUS HYPERREACTIVITY; CATHETER COMPLICATION; CATHETER SITE SWELLING; CHILD; CHILDHOOD DISEASE; CONSTIPATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EUROPEAN AMERICAN; EXTRAVASATION; FEMALE; FUNGEMIA; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFANT; INFUSION SITE EXTRAVASATION; INFUSION SITE PAIN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEWBORN; OPEN STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRURITUS; PSOAS ABSCESS; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SCHOOL CHILD; SIDE EFFECT; STEADY STATE; SWELLING; ULCERATIVE COLITIS;

ADOLESCENT; AGE FACTORS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOMEPRAZOLE SODIUM; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; PROTON PUMP INHIBITORS;

EID: 84864622972     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.028     Document Type: Article

References (19)

1. Sherman P.M., Hassall E., Fagundes-Neto U., et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009, 104:1278-1295.
2. DeVault K.R., Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:190-200.
3. Vandenplas Y., Rudolph C.D., Di Lorenzo C., et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009, 49:498-547.
4. Metz D.C. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000, 62:73-81.
5. NEXIUM (esomeprazole magnesium) [prescribing information] 2011, AstraZeneca Pharmaceuticals LP, Wilmington, DE.
6. NEXIUM IV (esomeprazole sodium) [prescribing information] 2011, AstraZeneca Pharmaceuticals LP, Wilmington, DE.
7. Metz D.C., Miner P.B., Heuman D.M., et al. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005, 22:813-821.
8. Stedman C.A.M., Barclay M.L. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000, 14:963-978.
9. Kearns G.L., Winter H.S. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 2003, 37(Suppl 1):S52-S59.
10. Omari T., Davidson G., Bondarov P., et al. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007, 45:530-537.
11. Lind T., Rydberg L., Kylebäck A., Jonsson A., et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14:861-867.
12. WHO Growth Standards Are Recommended for Use in the U.S. for Infants and Children 0 to 2 Years of Age Accessed May 30, 2012. http://www.cdc.gov/growthcharts/who_charts.htm.
13. Clinical growth charts Centers for Disease Control and Prevention, Accessed May 30, 2012. http://www.cdc.gov/growthcharts/clinical_charts.htm.
14. Declaration of Helsinki. BMJ 1996, 313:1448-1449. World Medical Organization, Accessed May 30, 2012. http://www.cirp.org/library/ethics/helsinki/.
15. International Conference on Harmonisation Good Clinical Practice, Accessed May 30, 2012. http://ichgcp.net/.
16. Zhao J., Li J., Hamer-Maansson J.E., et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006, 28:1868-1876.
17. Li J., Zhao J., Hamer-Maansson J.E., et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006, 28:419-427.
18. Kearns G.L., Blumer J., Schexnayder S., et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol 2008, 48:1356-1365.
19. Faure C., Michaud L., Shaghaghi K., et al. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr 2001, 33:144-148.